质量水平
ligand
(Trimethylammoniumethyl)
无菌性
sterile (Caustic Stable)
产品线
Eshmuno®
表单
resin
特殊分析物
MAbs
参数
1000 cm/hr flow rate
1000 cm/hr max. flow rate
8 bar max. pressure
基质活性基团
polymer, polyvinyl ether
平均粒径
85 μm
容量
150 mg binding capacity (BSA/mg of resin)
~150 mg, BSA binding capacity
转变温度
flash point 35 °C (own results)
密度
1 g/cm3 at 20 °C
应用
recombinant protein
vaccine development
分离技术
anion exchange
mixed mode
储存温度
2-30°C
正在寻找类似产品? 访问 产品对比指南
一般描述
特点和优势
- Purification of acidic and neutral proteins and peptides from different sources, including plasma
Superior productivity for downstream processing of biomolecules
- High flow rate versus pressure-flow behavior
- Excellent removal of impurities, such as HCP, leached Protein A, and viruses
- Robust and safe packing procedures
- Strong chemical stability
包装
- 1.20079.0100: Eshmuno® Q Resin 100ml
- 1.20079.0010: Eshmuno® Q Resin 10ml
- 1.20079.0500: Eshmuno® Q Resin 500ml
- 1.20079.5000: Eshmuno® Q Resin 5L
分析说明
Microscopic evaluation: Spherical particles, no agglomerates, no fines.
Extractable matter (water): ≤ 0.08 %
Ionic capacity: 90 - 190 µeq/ml
Performance test (conalbumin): 9 - 19 mS/cm
Performance test (human serum albumin): 20 - 30 mS/cm
Pressure drop(column: ID=1.6 cm, L=10 cm at 5 ml/min): ≤ 1.0 bar
Protein binding capacity(bovine serum albumin): 120 - 190 mg/ml
Particle size (50-120 µm): ≥ 80 %
Particle size (d50): 75 - 95 µm
Cerium: ≤ 30 µg/g
Endotoxins: ≤ 1.00 EU/ml
TAMC (total aerobic microbial count): ≤ 100 CFU/ml
TYMC (total yeast and mould count): ≤ 100 CFU/ml
法律信息
警示用语:
Warning
危险声明
危险分类
Flam. Liq. 3
储存分类代码
3 - Flammable liquids
WGK
WGK 1
闪点(°F)
95.0 °F
闪点(°C)
35 °C
商品
Separation and purification of subpopulations of extracellular vesicles (EVs) using Eshmuno® Q anion exchange resin and Natrix® Q membrane chromatography.
See case study examples of how to optimize chromatographic purification of plasmid DNA for Biopharmaceutical Applications.
Minimize bottlenecks in downstream processing. Discover how flow-through technologies increase speed and efficiency, reducing footprint and costs.
Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.
相关内容
通过合作进行量身定制的病毒疫苗生产,应对病毒特有的挑战。
This technical article breaks down the adenovirus vaccine manufacturing process and provides a case study on developing an accelerated and cost-effective single-use adenoviral vector vaccine.
Learn more on mAb downstream processing, more specifically polishing chromatography and the relevant associated products.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持